Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06754852 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
A Phase 1 study, sponsored by Hemab ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT06754852: Recruiting Phase 1 study, sponsored by Hemab ApS.
NCT06754852 is a Phase 1 study that is actively recruiting participants, run by Hemab ApS. The registered enrollment target is 108 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06754852, a Phase 1 study, is actively recruiting participants, sponsored by Hemab ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.
Interventions
- DRUG HMB-002 (Part A)
- DRUG HMB-002 (Part B)
- DRUG HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT06754852 shows while recruiting
NCT06754852 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% higher).
The record links to 0 conditions, and to 3 interventions - of which HMB-002 (Part A) is the first listed.
NCT06754852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06754852 about?
NCT06754852 is a clinical study titled "A Study Assessing HMB-002 in Participants With Von Willebrand Disease". This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safe...
What is the current status of trial NCT06754852?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2025-02-06. Estimated completion is 2027-07.
What interventions are being tested in trial NCT06754852?
The interventions under investigation include: HMB-002 (Part A) (DRUG), HMB-002 (Part B) (DRUG), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) (DRUG).
Who is sponsoring clinical trial NCT06754852?
This trial is sponsored by Hemab ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06754852's enrollment target sits among peer trials
108 523rd of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI